Mark J. Foley
Chief Executive Officer
Mark Foley is CEO of Revance Therapeutics and has served as a member of the Company’s board of directors since September 2017.
Previously, Mr. Foley was Chairman, President and CEO of ZELTIQ Aesthetics (ZLTQ). During his tenure, he led ZELTIQ’s growth from $68 million in annual revenue in 2012 to over $350 million in 2016, resulting in an appreciation of the Company’s stock of greater than tenfold and acquisition by Allergan (AGN) in April of 2017 for $2.5B. Mr. Foley also served as a Managing Director of RWI Ventures, a venture capital firm focused on life sciences, networking, semiconductor and software investments, from 2004 to 2018.
Mr. Foley has over 25 years of experience in the health care field, having served in a variety of senior operating roles in both large public companies and venture-backed startups, including U.S. Surgical Corporation, Guidant Corporation, Devices for Vascular Intervention (acquired by Eli Lilly), Perclose (acquired by Abbott) and Ventrica (acquired by Medtronic), where he was the founder and CEO. Also, he has partnered with a number of entrepreneurs to assist with the formation and capitalization of new health care companies while also serving as a Senior Advisor, Executive Chairman, interim CEO and board member to a number of medical device companies.
Mr. Foley currently serves on the board of directors of Glaukos (GKOS) and as chairman of the board for ULab. He also co-chairs the Aesthetics Innovation Summit and was chairman of Arrinex up and until its acquisition by Stryker in the spring of 2019. Mr. Foley received his BA from the University of Notre Dame in 1987 and is a named inventor on 17 patent applications.